Holen Sie sich die Stockscreener-App
145.31
0.43%
0.62
Handel nachbörslich:
145.31
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen (BIIB) to Report Q3 Earnings Amid IPR&D Expense Impact - GuruFocus
Biogen sees negative impact on Q3 EPS from IPR&D expense - Seeking Alpha
Biogen expects $2 million research and development expense in Q3 2025 - Investing.com India
Biogen expects estimated charge to impact net income per diluted share for Q3 by $-0.01 - MarketScreener
CD40 Targeting Therapy Clinical Trials Anti CD40 Antibody Therapy Market Opportunity Assessment Insight - GlobeNewswire Inc.
Wedbush Raises Price Target on Biogen to $135 From $129, Keeps Neutral Rating - MarketScreener
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - ACN Newswire
Can Biogen Inc. stock double in next 5 yearsProduct Launch & Stepwise Entry/Exit Trade Alerts - newser.com
Volatility clustering patterns for Biogen Inc.Weekly Profit Analysis & Real-Time Sentiment Analysis - newser.com
1 Healthcare Stock to Research Further and 2 We Find Risky - FinancialContent
Eisai and Biogen's LEQEMBI IQLIK™ Named One of TIME's "Best Inventions of 2025" for Alzheimer's Treatment - Quiver Quantitative
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - PR Newswire
Is a relief rally coming for Biogen Inc. holdersJuly 2025 Catalysts & Capital Efficiency Focused Strategies - newser.com
Key metrics from Biogen Inc.’s quarterly dataJuly 2025 Opening Moves & Safe Entry Point Alerts - newser.com
Is Biogen Inc. stock a top momentum playTrade Risk Assessment & Capital Efficiency Focused Ideas - newser.com
Biogen Inc. (BIIB) Stock Analysis: Exploring a 17% Potential Upside Amidst Robust Neurological Portfolio - DirectorsTalk Interviews
Using portfolio simulators with Biogen Inc. includedEarnings Risk Report & Community Driven Trade Alerts - newser.com
Valeo Financial Advisors LLC Invests $225,000 in Biogen Inc. $BIIB - MarketBeat
UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know - The Globe and Mail
BIIB: Morgan Stanley Raises Price Target for Biogen to $149 | BI - GuruFocus
Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines? - Yahoo Finance
Biogen and Stoke add to zorevunersen data package in Dravet syndrome - The Pharma Letter
Biogen Inc.'s (NASDAQ:BIIB) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue? - 富途牛牛
Biogen, Stoke Therapeutics Present Positive Long-Term Data for Zorevunersen in Dravet Syndrome - MarketScreener
Q3 Earnings Estimate for Biogen Issued By Leerink Partnrs - MarketBeat
Using data filters to optimize entry into Biogen Inc.2025 EndofYear Setup & Stock Portfolio Risk Control - newser.com
What to Expect From Biogen’s Q3 2025 Earnings Report - MSN
Layoff Tracker: Ferring To Cut 500 Employees as Part of Business Model Shift - BioSpace
Biogen And Stoke Therapeutics Present Promising Long-Term Data For Zorevunersen In Dravet Syndrome - Nasdaq
Biogen (NASDAQ:BIIB) Earns Sell (D+) Rating from Weiss Ratings - MarketBeat
Biogen invests $250,000 into Durham Tech’s Life Sciences Center - CBS 17
Biogen's (BIIB) Zorevunersen Shows Promise in Treating Dravet Sy - GuruFocus
Biogen and Stoke Therapeutics Announce Positive Long-Term Results of Zorevunersen in Dravet Syndrome at Child Neurology Society Annual Meeting - Quiver Quantitative
Biogen and Stoke Therapeutics Present New Data at the 54th - GlobeNewswire
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome - FinancialContent
Where Does Biogen Stand After Recent 7% Rally Amid Alzheimer’s Drug Developments? - simplywall.st
Biogen's Comeback: Why The Bulls Are Finally Winning Again (NASDAQ:BIIB) - Seeking Alpha
NC governor recognizes Biogen milestone as biotech giant celebrates recent investments in Triangle - CBS 17
Is Biogen Inc. (IDP) stock a defensive play amid uncertainty2025 Fundamental Recap & Weekly High Return Forecasts - newser.com
Biogen Pledges $250,000 Donation to Durham Technical Community College to Mark 30th Year Anniversary in Research Triangle Park - Biogen
Eisai and Biogen Leqembi Iqlik: The Best Inventions of 2025 - Time Magazine
Simplicity Wealth LLC Makes New $430,000 Investment in Biogen Inc. $BIIB - MarketBeat
Why Are Analysts Bullish on Biogen Inc. (BIIB) Now? - MSN
Governor Stein to celebrate Biogen's 30th anniversary, spotlight biotech growth - WCTI
Zenas Looks To Target Progressive Multiple Sclerosis Via InnoCare Deal - insights.citeline.com
Can BMYs Neuroscience Portfolio Help to Diversify Its Business? - The Globe and Mail
Biogen Leqembi at-home maintenance dose for Alzheimer's available - MSN
Biogen stock price target lowered to $217 from $219 at RBC Capital - Investing.com
What To Expect From Biogen’s Q3 2025 Earnings Report - Barchart.com
Royal Bank Of Canada Lowers Biogen (NASDAQ:BIIB) Price Target to $217.00 - MarketBeat
Central Nervous System Biomarkers Market Growth & Industry - openPR.com
Leerink Partnrs Issues Negative Forecast for Biogen Earnings - MarketBeat
Biogen Inc. stock underperforms Monday when compared to competitors - MSN
Biogen Inc. $BIIB Shares Purchased by KLP Kapitalforvaltning AS - MarketBeat
Ascent Group LLC Takes $341,000 Position in Biogen Inc. $BIIB - MarketBeat
Biogen Says Investors Can't Expand Alzheimer's Drug Suit - Law360
Biogen, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syn - PharmiWeb.com
Biogen (BIIB) Sees Decline After Launching New Alzheimer's Drug Formulation - GuruFocus
Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes - Yahoo Finance
Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syngenta, Biocon, Biogen, F. Hoffmann-La Roche, Novartis, Novo Nordisk A/S, Pfizer, and SeagenResearchAndMarkets.com | FinancialContent - FinancialContent
Bioarctic's Leqembi Maintenance Therapy Launched in the United States - MarketScreener
Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug - GuruFocus
Biogen (BIIB) Launches New Alzheimer's Treatment in the U.S. - GuruFocus
Eisai and Biogen Announce U.S. Availability of LEQEMBI® - GlobeNewswire
Leqembi Iqlik subcutaneous injection now available in US By Investing.com - Investing.com Australia
0.86%
0.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):